GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (BSP:G1LP34) » Definitions » Cyclically Adjusted Revenue per Share

Galapagos NV (BSP:G1LP34) Cyclically Adjusted Revenue per Share : R$1.79 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Galapagos NV Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Galapagos NV's adjusted revenue per share for the three months ended in Mar. 2025 was R$0.354. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$1.79 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Galapagos NV's average Cyclically Adjusted Revenue Growth Rate was 4.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Galapagos NV was 1.90% per year. The lowest was 1.20% per year. And the median was 1.55% per year.

As of today (2025-05-30), Galapagos NV's current stock price is R$8.14. Galapagos NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was R$1.79. Galapagos NV's Cyclically Adjusted PS Ratio of today is 4.55.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Galapagos NV was 35.11. The lowest was 3.62. And the median was 7.12.


Galapagos NV Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Galapagos NV's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Cyclically Adjusted Revenue per Share Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.72 1.70 1.45 1.49 1.81

Galapagos NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.52 1.67 1.69 1.81 1.79

Competitive Comparison of Galapagos NV's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Galapagos NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Cyclically Adjusted PS Ratio falls into.


;
;

Galapagos NV Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Galapagos NV's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.354/134.3475*134.3475
=0.354

Current CPI (Mar. 2025) = 134.3475.

Galapagos NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.060 100.107 0.081
201509 0.032 100.245 0.043
201512 0.039 100.572 0.052
201603 0.046 101.653 0.061
201606 0.115 102.267 0.151
201609 0.043 102.118 0.057
201612 0.304 102.614 0.398
201703 0.123 103.972 0.159
201706 0.099 103.902 0.128
201709 0.100 104.170 0.129
201712 0.151 104.804 0.194
201803 0.150 105.419 0.191
201806 0.211 106.063 0.267
201809 0.429 106.618 0.541
201812 0.392 107.252 0.491
201903 0.131 107.876 0.163
201906 0.233 107.896 0.290
201909 2.401 107.470 3.001
201912 0.371 108.065 0.461
202003 0.376 108.550 0.465
202006 0.448 108.540 0.555
202009 0.619 108.441 0.767
202012 0.748 108.511 0.926
202103 0.571 109.522 0.700
202106 0.646 110.305 0.787
202109 0.304 111.543 0.366
202112 -0.408 114.705 -0.478
202203 0.561 118.620 0.635
202206 0.559 120.948 0.621
202209 0.537 124.120 0.581
202212 -0.774 126.578 -0.822
202303 0.246 126.528 0.261
202306 0.242 125.973 0.258
202309 0.243 127.083 0.257
202312 0.245 128.292 0.257
202403 0.257 130.552 0.264
202406 0.344 130.691 0.354
202409 0.277 130.968 0.284
202412 0.366 132.346 0.372
202503 0.354 134.348 0.354

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Galapagos NV  (BSP:G1LP34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Galapagos NV's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=8.14/1.79
=4.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Galapagos NV was 35.11. The lowest was 3.62. And the median was 7.12.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Galapagos NV Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (BSP:G1LP34) » Definitions » Cyclically Adjusted Revenue per Share
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV Headlines

No Headlines